StreetInsider.com News Articles

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 16:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received in the aggregate 211,070 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date,

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 16:30:00 -0400

The employees received in the aggregate 211,070 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date,

Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorgan

Wed, 30 Sep 2026 09:09:35 -0400

JPMorgan analyst Anupam Rama lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $20.00 (from $23.00) while maintaining a Neutral rating.

Sarepta's Elevidys shows benefit in older Duchenne patients

Wed, 30 Sep 2026 08:31:29 -0400

Sarepta Therapeutics (NASDAQ: SRPT) presented new data at the 31st Annual Congress of the World Muscle Society showing that its gene therapy Elevidys (delandistrogene moxeparvovec) produced statistically significant functional benefits in ambulatory Duchenne muscular dystrophy patients aged 8 to 12 over two years, compared to a well-matched external control group.

The analysis drew from the EMBARK and ENDEAVOR studies, comparing 25 treated patients against 99 external controls. Treated patients showed a 3.32-point improvement on the North Star Ambulatory Assessment (p=0.0022), a 0.041 rise/second improvement in time-to-rise-from-floor velocity (p=0.0019), and a 0.195 meters/second improvement in 10-meter walk run velocity (p=0.0114). The safety

Sarepta's Elevidys shows benefit in older Duchenne patients

Wed, 30 Sep 2026 08:31:29 -0400

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde

Wed, 30 Sep 2026 08:30:00 -0400

Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a well-matched external control group

Separate findings in children treated at ages 2 to under 3 demonstrated robust delandistrogene moxeparvovec-dystrophin expression and transduction efficiency at 12 weeks

In these analyses, the safety profile of delandistrogene moxeparvovec remained consistent and no new signals were identified

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde

Wed, 30 Sep 2026 08:30:00 -0400

Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a well-matched external control group

Separate findings in children treated at ages 2 to under 3 demonstrated robust delandistrogene moxeparvovec-dystrophin expression and transduction efficiency at 12 weeks

In these analyses, the safety profile of delandistrogene moxeparvovec remained consistent and no new signals were identified

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Fri, 25 Sep 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan.

Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta’s clinical studies who were aged 8-12 years old at the time of treatment.

Poster numbers, titles and session timing are as follows:

Sarepta to present Phase 4 Duchenne drug data at neuromuscular meeting

Thu, 24 Sep 2026 08:30:52 -0400

Sarepta Therapeutics (NASDAQ: SRPT) plans to present seven posters at the 27th Annual Neuromuscular Study Group Scientific Meeting, scheduled for Sept. 25-27, 2026, in San Antonio, Texas, according to a company statement.

Among the presentations are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvovec — sold as Elevidys — as part of clinical care for Duchenne muscular dystrophy. The data include safety findings in patients who received prophylactic immunosuppression with sirolimus.

Five of the seven posters focus on Duchenne muscular dystrophy. Topics include a pooled analysis examining the association between micro-dystrophin

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Thu, 24 Sep 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas.

Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvovec as part of clinical care for Duchenne muscular dystrophy, including safety in patients who received prophylactic immunosuppression with sirolimus.

“The data being presented at NMSG 2026 provide new insights into

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Thu, 24 Sep 2026 08:30:00 -0400

“The data being presented at NMSG 2026 provide new insights into

Form 8-K Sarepta Therapeutics, For: Sep 23

Wed, 23 Sep 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260923/27096863.html

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

Analysts at Mizuho remain optimistic about the prospects of one biotech company whose shares fell in response to the announcement from Novartis (NYSE: NVS) that its HARBOR Phase 3 study had failed to achieve its primary endpoint.

Sarepta Therapeutics (NASDAQ: SRPT) stock was down 10% (and has been volatile since) following the announcement, amid concerns that the company’s SRP-1003 targeting myotonic dystrophy type 1 (DM1) might similarly disappoint.

The HARBOR Phase 3 trial did not demonstrate a statistically significant improvement versus placebo in video hand opening time (vHOT), a measure of hand myotonia/function. HARBOR was a pivotal, randomized, placebo-controlled study of 159

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Wed, 09 Sep 2026 07:28:06 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating and $5.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst commented: "Novartis' ~150-patient, 54-week Phase 3 HARBOR study of del-desiran missed its placebo-controlled vHOT primary endpoint after MARINA had shown ~40% mean DMPK mRNA reduction, splicing correction and an approximately 2-3-second vHOT improvement at Year 1. That early functional magnitude is similar to the ~3-second vHOT changes subsequently reported with Dyne's (DYN; Ghosh; Buy) z-basivarsen and PepGen's (PEPG; Ghosh; Buy) PGN-EDODM1. We believe the read-through is particularly relevant for Sarepta because the marketed DMD story has continued to lose support:

Jefferies: 'we can still see at least a +25-50% stock move if SRPT shows competitive/superior 6-month splicing/vHOT data'

Tue, 08 Sep 2026 13:25:57 -0400

Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "Other thoughts/points: (1) A pot'l caveat is how SRP-1003's Phase I/II update could contain a Month 6 datacut, but seeing benefits on outcomes (e.g. QMT, 10MWR, MDHI, DM1-Active) may take longer to demonstrate efficacy. As such, reporting possibly only vHOT/splicing data in H2:26 could force the debate to linger. (2) Seeing a benefit on actual outcome measures (not vHOT) should drive uptake in the large 40K+ US patient TAM, as corroborated by our KOL checks (here, here, here) and del-desiran's own

Mizuho Defends Sarepta Therapeutics (SRPT)

Tue, 08 Sep 2026 10:53:35 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying the HARBOR sell-off is overdone.

The analyst commented, "We believe the sell-off (-10% vs. -1% XBI) due to Novartis' failed HARBOR Phase 3 study of del-desiran in DM1 is overdone. In our view, the press release contains little information about the Phase 3 results to draw broad negative readthroughs to Sarepta's SRP-1003. It's not clear why del-desiran missed the vHOT primary endpoint, but del-desiran seems to work, as Novartis noted that it showed evidence of clinical activity in secondary endpoints and exploratory analyses

Mizuho Defends Sarepta Therapeutics (SRPT)

Tue, 08 Sep 2026 10:53:35 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying the HARBOR sell-off is overdone.

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Tue, 08 Sep 2026 09:00:00 -0400

Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition

Now in its ninth year, program has awarded more than 150 scholarships

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne.

Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Tue, 08 Sep 2026 09:00:00 -0400

Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition

Now in its ninth year, program has awarded more than 150 scholarships

Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Mon, 31 Aug 2026 16:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET.

The presentation will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that